91296-17-2

Upstream product

• 42351-81-5 hydrazinoacetaldehyde diethyl acetal 
• 123-06-8 Ethoxymethylenemalononitrile 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 16617-46-2 3-amino-4-cyano-2H-pyrazole 

Downstream Products

• 91296-21-8 imidazo<1,2-b>pyrazole-7-carboxamide 
• 91296-27-4 5-β-D-ribofuranosylimidazo<1,2-b>pyrazole-7-carbonitrile 
• 91296-23-0 1-β-D-ribofuranosylimidazo<1,2-b>pyrazole-7-carbonitrile 
• 91296-28-5 1-β-D-ribofuranosylimidazo<1,2-b>pyrazole-7-carboxamide 
• 91296-26-3 5-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)imidazo<1,2-b>pyrazole-7-carbonitrile 
• 91296-22-9 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)imidazo<1,2-b>pyrazole-7-carbonitrile 
• 135830-04-5 1-methyl-1H-imidazo[1,2-b]pyrazole-7-carbonitrile 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, p

COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

Cephem compounds

Cephem compounds of the following formula are disclosed: STR1 wherein R1 is amino or protected amino group. R2 is H or an organic group, R3 is H or an organic group, R4 is H, lower alkyl, carboxy, protected carb